Sepsis/SIRS/MODS Flashcards

1
Q

Which molecule brought by albumin is protective of the endothelial glycocalyx?

A

Erythrocyte-derived sphingosine-1-phosphate (Suppress matrix metalloproteinase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are components of the immunosuppression during sepsis?

A

Dysregulated compensatory anti-inflammatory response, lymphocyte exhaustion, increased tolerance to endotoxins, dyregulated expansion of T-regulatory cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Name determinants of immunoparalysis in sepsis (6)

A
Macrophage deactivation
Negative regulatory mediators
Increased apoptosis
Increased anti-inflammatory mediators
Altered energy uptake 
Suppression of immune cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Name risk factors for antimicrobial resistance (6)

A

Antibiotic within the past 3 months
Environment with high frequency of resistance (Hospital, community)
Immunosuppressive therapy or disease
Bacterial translocation from GI tract
Invasive procedures
Placement of foreign material with surface conductive to bacterial colonization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Name the two bacteria that are the major part of GI microflora

A

Enterococcus (Gram +) and E.coli (Gram -)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define MDR, XDR and PDR

A

MDR: Resistance to 3 or more antibiotic families to which the antibiotic is naturally susceptible
XDR: Sensitivity to only 1 or 2 antibiotics
PDR (Pandrug resistance): Resistance to all antibiotic families

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define a nosocomial infection

A

Infection that the patient acquired in the hospital, arising more than 48 hours after hospital admission, within a week of discharge or within a month of surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the decline in survival per hour of antibiotic delay in septic shock (people)?

A

7.6%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which type of antibiotics can have antagonistic effects in combination therapy?

A

Combination of a drug that inhibits ribosomes (chloramphenicol, tetracycline, erythromycin) with a drug that relies on protein synthesis for the bactericidal activity (Beta-lactam, fluoroquinolone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give an example of a synergic antibiotic combination therapy

A

Ampicillin with gentamicin (Cell wall agent promote entry of gentamicin into cell) for enterococcus, enterobacter, pseudomonas and MRSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are three major factor to consider in the dosing regimen of antibiotics?

A

MIC of the infecting microbe
Plasma and tissue drug concentration and the site of infection
Impact of microbial and host factors impacting the drug concentration at site of infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Time dependent antibiotic have a ___________ (reversible/irreversible) action on their target?

A

Reversible (Cell wall inhibitors, folic acid inhibitors, bacteriostatic atbs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the appropriate magnitude of Cmax/MIC in concentration-dependent antibiotics?

A

10-12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the best measurement of effectiveness for concentration-dependent antibiotic? What value is associated with bacteria killing and decreased resistance?

A

Area under the inhibitory curve. AUIC >100-125 generally associated with bacterial killing and decreased resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the three levels (Blood vessel barrier) of drug penetration in normal tissues?

A

1) Sinusoidal capillaries; No barrier to bound or unbound drugs (Adrenal cortex, pituitary gland, liver and spleen)
2) Fenestrated capillaries; Pore permeable to unbound drugs (Kidneys, endocrine glands). **Protein bound drugs will not diffuse as well, and MIC might be underestimated (Doxycycline)
3) Continuous (Non-fenestrated); Tight junction prevent drug movement (Brain, CSF, testes, prostate, muscles)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

____________ (lipid/water) soluble antibiotics penetrate better in organs with continuous capillaries?

A

Lipid (30-80% penetration vs 2-30% in bronchial secretion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the two main causes of expansion of volume of distribution in critical patients?

A

Septic shock and trauma (Third spacing/edema)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the inoculum effect?

A

Larger inocula have a higher bacterial load/target, this require more drug molecules
Larger inocula have a greater risk of spontaneous mutation and produce more destructive enzumes

19
Q

How can nephrotoxicity to aminoglycoside be prevented?

A

1) Once daily administration with trough <1.2mg/ml
2) Hydration of patient
3) Morning administration (to promote drinking)
4) Avoid nephroactive drugs

20
Q

What are the benefit of antimicrobial de-escalation?

A

Cost minimization, reduction in adverse events, reduced risk of antimicrobial resistance, decreased incidence of infections related to antimicrobial use (C. difficile diarrhea, superinfection, fungal/Candida)

21
Q

Which families of antibiotics are included in beta-lactam antimicrobials?

A

Penicillin, cephalosporin, carbapenem

22
Q

What are two types of resistance against beta-lactam antibiotics?

A

Beta-lactamase produciton

Change in cell wall permeability (mecA gene modifies PBP2a in methicillin resistance)

23
Q

What are the benefits of meropenem over imipenem?

A

More soluble, less nephrotoxic, can be administered quicker

24
Q

What is the adaptive resistance of bacteria?

A

Capacity to decrease the update of an antibiotic after the first dose, more likely if low Cmax after administration (e.g. aminoglycoside and pseudomonas)

25
Q

What is the inhibitory quotient?

A

Cmax/MIC; Must be > 8-12 for effective bacterial killing of concentration dependent antibiotics

26
Q

What conditions can alter the volume of distribution?

A

Vascular leak syndrome, edematous states, hypoalbuminemia, SIRS, mechanical ventilation, extensive burns, severe trauma, aggressive intravenous fluid therapy, parenteral nutrition

27
Q

Name risk factors for aminoglycoside-induced nephrotoxicity?

A

Advanced age, duration of therapy, fever, volume depletion, dehydration, nephroactive drugs, preexisting kidney disease, potassium/magnesium depletion

28
Q

Name adverse events related to aminoglycoside administration

A

Neuromuscular paralysis- Interference with release and uptake of ACh in the NMJ and inhibition of calcium movement into the nerve terminal. Can be treated with calcium infusion or cholinesterase

Ototoxicity/vestibulocochlear toxicity

Nephrotoxicity: Uptake by proximal tubular cells and high concentration in lysosomes cause cell disruption. Single-daily-dosing and monitor for granular/cellular cast and proteinuria/glucosuria recommended

29
Q

What are strategies to avoid nephrotoxicity with aminoglycoside

A

1) Single daily dosing (In the morning)
2) Hydration of patient
3) Therapeutic drug monitoring with drug free interval of 2-4 hrs
4) Discontinuation of nephroactive drugs
5) Cautious use in patients with variable volume of distribution (Sepsis, edema, burns,…)

30
Q

What is the target of action for fluoroquinolone?

A

DNA gyrase (primary target) and topoisomerase IV

31
Q

Define postantibiotic effect.

A

Period of time after serum drug concentration falls below the MIC that bacterial growth continues to be inhibited
(E.g. fluoroquinolones, aminoglycosides)

32
Q

What are the mechanisms of resistance against fluoroquinolones

A

1) Mutation of the target- Gene mutation of DNA gyrase (Gram -) and topoisomerase IV (Gram +)
2) Increased expression of efflux pump (E. Coli and Salmonella)
3) Altering outer membrane porins to prevent passive diffusion of the drug into cytoplasm
4) Plasmid

33
Q

Fluoroquinolones have ___________ (higher/lower) concentration in lungs, bile, prostate and urine compared to serum.

A

Higher

34
Q

Fluoroquinolones are ________ (Ineffective/effective) against intracellular organisms,

A

Effective- Accumulation in neutrophils and macrophages, activity against mycoplasma, mycobacteria, chlamydia and brucella

35
Q

Administration of oral antiacids ________ (Increase/decrease/does not affect) absorption of fluoroquinolones and food ________ (Increase/decrease/does not affect) its absoprtion.

A

1) Decrease

2) Does not affect (but delays peak serum)

36
Q

How do fluoroquinolones cause seizures?

A

Inhibition of GABA receptors and stimulation of NDMA receptors

37
Q

How do fluoroquinolone cause cartilage damage in juvenile animals?

A

Inhibition of proteoglycans synthesis, chelation of magnesium, inhibition of mitochondrial dehydrogenase activity

38
Q

Name three major adverse events associated with fluoroquinolone use.

A
  • Seizures and neurological abnormalities
  • Cartilage defect in juvenile patients
  • Retinal degeneration and blindness in cats
39
Q

Name three major adverse events associated with fluoroquinolone use.

A
  • Seizures and neurological abnormalities
  • Cartilage defect in juvenile patients
  • Retinal degeneration and blindness in cats
40
Q

Which parameters are used for SIRS criteria?

A

Temperature
Heart rate
Respiratory rate
WBC count

41
Q

What are the parameters for SIRS criteria in dogs?

A

T <100.6 or > 102.6
HR >120
RR>20
WBC >16K, <6K or band >3%

42
Q

What are the parameters for SIRS criteria in cats?

A

T <100, > 104
HR <140, > 225
RR >40
WBC <5K or >19K

43
Q

What is the definition of sepsis based on Sepsis-3?

A

Life-threatening organ dysfunction secondary to an infectious process

44
Q

What is the definition of septic shock based on sepsis-3?

A

Life-threatening circulatory, metabolic and cellular dysfunction secondary to an infectious agent.
Clinically, requirement for vasopressor or lactate >2mmol/L despite normovolemia